Up next

Autoplay

CALQUENCE® (acalabrutinib) Perspectives: Dr Alexey Danilov, MD, PhD

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Please see full Prescribing Information: https://qr.short.az/CalquenceUSPI
This video is intended for US healthcare professionals only.

Dr. Danilov discusses CALQUENCE in preclinical assays and ELEVATE-TN data.

Topics include mechanism of disease (MOD), CALQUENCE® (acalabrutinib) selectivity, and patients with high-risk cytogenetics.

Indications and Select Safety Information
CALQUENCE is indicated in combination with bendamustine and rituximab (BR) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT), as monotherapy for the treatment of adult patients with MCL who have received at least one prior therapy, and for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are diarrhea, upper respiratory tract infection, headache, musculoskeletal pain, lower respiratory tract infection, and fatigue. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, absolute lymphocyte count decreased, platelets decreased, and hemoglobin decreased.

Show more
0 Comments sort Sort By

Up next

Autoplay